Cardiotoxicity with doxorubicin, trastuzumab, and development of the metabolic syndrome: Case report
DOI:
https://doi.org/10.33448/rsd-v10i5.15037Keywords:
Cardiotoxicity; Doxorubicin; Trastuzumab; Metabolic Syndrome.Abstract
The aim of this report is to present a case of a breast cancer patient who showed a reduction in the left ventricular ejection fraction and developed the metabolic syndrome after doxorubicin and trastuzumab use. It was analyzed if those drugs may be related to cardiotoxicity or be a possible cause for metabolic syndrome. With increased cancer survival, many patients may still develop metabolic syndrome, which has a multifactorial nature A 46-year-old female patient with infiltrated breast cancer exhibiting reduced left ventricular ejection fraction after chemotherapy neoadjuvant with doxorubicin and then with isolated trastuzumab. Chemotherapy was discontinued, and it was prescribed tamoxifen. The patient was referred to the cardiologist and nutritionist for a follow-up of the metabolic syndrome. Importance of early identification and monitoring of cardiotoxicity, avoiding the cardiovascular complications of cancer treatment and the preventing interruption of therapy.
References
Brant, L., Nascimento, B. R., Passos, V., Duncan, B. B., Bensenõr, I., Malta, D. C., Souza, M., Ishitani, L. H., França, E., Oliveira, M. S., Mooney, M., Naghavi, M., Roth, G., & Ribeiro, A. (2017). Variations and particularities in cardiovascular disease mortality in Brazil and Brazilian states in 1990 and 2015: estimates from the Global Burden of Disease. Variações e diferenciais da mortalidade por doença cardiovascular no Brasil e em seus estados, em 1990 e 2015: estimativas do Estudo Carga Global de Doença. Revista brasileira de epidemiologia = Brazilian journal of epidemiology, 20Suppl 01(Suppl 01), 116–128.
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., ... & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213-220.
Ewer, M. S., Vooletich, M. T., Durand, J. B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005). Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23(31), 7820-7826.
Feitosa, F. S., Junior, C. V. S., Takemura, R. L., Graner, H., & Moreira, A. D. G. (2012). Metabolic syndrome and breast cancer: systematic review. Rev Bras Clin Med São Paulo, 10(6), 513-20.
Gunaldi, M., Duman, B. B., Afsar, C. U., Paydas, S., Erkisi, M., Kara, I. O., & Sahin, B. (2016). Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study. Journal of Oncology Pharmacy Practice, 22(2), 242-247.
Hajjar, L. A., Costa, I. B. S. D. S. D., Lopes, M. A. C. Q., Hoff, P. M. G., Diz, M. D. P. E., Fonseca, S. M. R., ... & Kalil Filho, R. (2020). Brazilian Cardio-oncology Guideline–2020. Arquivos Brasileiros de Cardiologia, 115(5), 1006-1043.
Henriksen P. A. (2018). Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart (British Cardiac Society), 104(12), 971–977.
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014, September). Evaluation and management of patients with heart disease and cancer: cardio-oncology. In Mayo Clinic Proceedings (Vol. 89, No. 9, pp. 1287-1306). Elsevier.
James, I. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).Special Communication. American Medical Association. JAMA.( Vol.285, No.19, pp.2486-2497).
Leite, A. D. M., Macedo, A. V. S., Jorge, A. J. L., & Martins, W. D. A. (2018). Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities–Systematic Review. Arquivos brasileiros de cardiologia, 111(2), 205-212.
Lorenzo, C., Williams, K., Hunt, K. J., & Haffner, S. M. (2007). The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes care, 30(1), 8-13.
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular drugs and therapy, 31(1), 63–75.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., ... & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239-245.
Nahas, E. A. P., Almeida, B. D. R. D., Buttros, D. D. A. B., Véspoli, H. D. L., Uemura, G., & Nahas-Neto, J. (2012). Síndrome metabólica em mulheres na pós-menopausa tratadas de câncer de mama. Revista Brasileira de Ginecologia e Obstetrícia, 34(12), 555-562.
Narezkina, A., & Nasim, K. (2019). Anthracycline Cardiotoxicity. Circulation. Heart failure, 12(3), e005910.
Nicolazzi, M. A., Carnicelli, A., Fuorlo, M., Scaldaferri, A., Masetti, R., Landolfi, R., & Favuzzi, A. (2018). Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. European review for medical and pharmacological sciences, 22(7), 2175–2185.
Pereira, A. S. et al. (2018). Metodologia da pesquisa cientifica. [free e-book]. Santa Maria:UAB/NTE/UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E., Jr, Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, N. E., Mamounas, E., Zujewski, J. A., & Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(33), 3744–3752.
Pituskin, E., Haykowsky, M., McNeely, M., Mackey, J., Chua, N., & Paterson, I. (2016). Rationale and design of the multidisciplinary team Intervention in cardio-oncology study (TITAN). BMC cancer, 16(1), 1-6.
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., ... & Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal–Cardiovascular Imaging, 15(10), 1063-1093.
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004). Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity reviews, 5(3), 153-165.
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M. C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., … Breast Cancer International Research Group (2011). Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine, 365(14), 1273–1283.
Sociedade Brasileira de Farmacêuticos em Oncologia (SOBRAFO). Agência Nacional de Vigilância Sanitária.Guia para Notificação de Reações Adversas em Oncologia. 2.ed. São Paulo: Conectfarma Publicações Científicas; 2011.
Wang, S. Y., Long, J. B., Hurria, A., Owusu, C., Steingart, R. M., Gross, C. P., & Chen, J. (2014). Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast cancer research and treatment, 146(2), 411–419.
Westerink, N. L., Nuver, J., Lefrandt, J. D., Vrieling, A. H., Gietema, J. A., & Walenkamp, A. M. E. (2016). Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Critical reviews in oncology/hematology, 108, 128-136.
Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology, 53(24), 2231–2247.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Patricia Marques Soares Valente; Thamires Ferreira Neves; Walter Claudino Pires de Souza; Eduardo Pinho Braga; Wolney de Andrade Martins; Selma Rodrigues de Castilho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
